MX2023002496A - Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso. - Google Patents

Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.

Info

Publication number
MX2023002496A
MX2023002496A MX2023002496A MX2023002496A MX2023002496A MX 2023002496 A MX2023002496 A MX 2023002496A MX 2023002496 A MX2023002496 A MX 2023002496A MX 2023002496 A MX2023002496 A MX 2023002496A MX 2023002496 A MX2023002496 A MX 2023002496A
Authority
MX
Mexico
Prior art keywords
vegf
methods
ang2
binds
antibody
Prior art date
Application number
MX2023002496A
Other languages
English (en)
Inventor
Joerg Moelleken
Christoph Ullmer
Christian Schantz
Guido Hartmann
Sebastian Fenn
Michael Molhoj
Roland Beckmann
Sabine Imhof-Jung
Barbara Weiser
Kristian Hobolt Jensen
Janina Speck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023002496A publication Critical patent/MX2023002496A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-VEGF-A/anti-ANG2, por ejemplo, en forma de un fragmento Fab biespecífico, y sus métodos de uso.
MX2023002496A 2020-09-04 2021-09-02 Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso. MX2023002496A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20194610 2020-09-04
EP20209591 2020-11-24
PCT/EP2021/074195 WO2022049165A1 (en) 2020-09-04 2021-09-02 Antibody that binds to vegf-a and ang2 and methods of use

Publications (1)

Publication Number Publication Date
MX2023002496A true MX2023002496A (es) 2023-03-09

Family

ID=77750299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002496A MX2023002496A (es) 2020-09-04 2021-09-02 Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.

Country Status (16)

Country Link
US (2) US11732036B2 (es)
EP (1) EP4208201A1 (es)
JP (2) JP7158626B1 (es)
KR (1) KR20230061458A (es)
CN (1) CN116323663A (es)
AU (1) AU2021335509A1 (es)
CA (1) CA3193163A1 (es)
CL (1) CL2023000595A1 (es)
CO (1) CO2023004251A2 (es)
CR (1) CR20230114A (es)
IL (1) IL300616A (es)
MX (1) MX2023002496A (es)
PE (1) PE20230986A1 (es)
TW (1) TW202227487A (es)
WO (1) WO2022049165A1 (es)
ZA (1) ZA202302084B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230986A1 (es) * 2020-09-04 2023-06-21 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y metodos de uso
WO2024085606A1 (ko) * 2022-10-20 2024-04-25 (주)니오테스바이오 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
JP4540229B2 (ja) 1998-07-23 2010-09-08 コオペラティ・アヴェベ・ユー・エイ 接着剤組成物
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
DE60336548D1 (de) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
EP2264151B1 (en) 2003-01-22 2016-04-20 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
EP3960134A1 (en) 2010-08-05 2022-03-02 ForSight Vision4, Inc. Implantable therapeutic device
EP2600920A4 (en) 2010-08-05 2017-10-04 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
SI2726510T1 (sl) 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dvojno ciljanje
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
ES2676031T3 (es) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
WO2015085234A1 (en) 2013-12-06 2015-06-11 Forsight Vision4, Inc. Implantable therapeutic devices
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
US11059885B2 (en) 2016-05-13 2021-07-13 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
CA3034574A1 (en) 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof
IL276383B2 (en) * 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
CN112262158A (zh) 2018-04-10 2021-01-22 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
TW202039552A (zh) * 2018-12-21 2020-11-01 瑞士商赫孚孟拉羅股份公司 結合至VEGF及IL-1β之抗體及使用方法
PE20230986A1 (es) * 2020-09-04 2023-06-21 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y metodos de uso

Also Published As

Publication number Publication date
US20220073599A1 (en) 2022-03-10
CL2023000595A1 (es) 2023-10-06
US20230374119A1 (en) 2023-11-23
KR20230061458A (ko) 2023-05-08
IL300616A (en) 2023-04-01
JP2022191367A (ja) 2022-12-27
JP7158626B1 (ja) 2022-10-21
CR20230114A (es) 2023-05-18
CA3193163A1 (en) 2022-03-10
CO2023004251A2 (es) 2023-06-30
AU2021335509A1 (en) 2023-03-09
PE20230986A1 (es) 2023-06-21
CN116323663A (zh) 2023-06-23
EP4208201A1 (en) 2023-07-12
WO2022049165A1 (en) 2022-03-10
TW202227487A (zh) 2022-07-16
ZA202302084B (en) 2023-11-29
JP2022545849A (ja) 2022-10-31
US11732036B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
ZA202302084B (en) Antibody that binds to vegf-a and ang2 and methods of use
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR106189A1 (es) ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
MD3463435T2 (ro) Anticorpi impotriva alfa sinucleinei și utilizări ale acestora
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
EA202190056A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.
AR119982A1 (es) Terapias de combinación con anticuerpos entpd2